1 |
|
Efficacy and Safety of Satralizumab from Two Phase 3 Trials in Neuromyelitis Optica Spectrum Disorder (Video) | Benjamin Frishberg, Jerome de Seze, Brian Weinshenker, Yusuke Terada, Yuichi Kawata, Athos Gianella-Borradori, H. Christianvon Büdingen, Gaelle Klingelschmitt, Anthony Traboulsee, Takashi Yamamura | Satralizumab is a humanized recycling monoclonal antibody that binds to the interleukin-6 (IL-6) receptor; IL-6 has been implicated in the pathophysiology of neuromyelitis optica spectrum disorder (NMOSD). Satralizumab was evaluated in patients with NMOSD in two Phase 3 studies: SAkuraSky (NCT020288... | 20200309_nanos_sciplatform1_03 |